Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and efficacy data for CTX110 in relapsed or refractory B-cell malignancies, including Non-Hodgkin lymphoma, from the C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CTX110

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: B-cell Malignancy, Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-10-24